Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) announced on 8/8/18 the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO (nivolumab), for the treatment of advanced ovarian cancer.